Jeff Borghoff and his wife Kimberly speak about participating in the Biogen drug trial testing aducanumab, a drug that targets beta-amyloid. The late-stage trial was recently canceled, news that sent participants, their families, researchers and stocks reeling.
[ Next: ‘They Are Still Here, and They Can Still Contribute’: What He Learned From Alzheimer’s at Age 51 ]
If you find our articles and interviews helpful, please consider becoming a supporting member of our community.
Frustrated by the lack of an editorially independent source of information on brain health and Alzheimer’s disease, we decided to create Being Patient.
We are a team of dedicated journalists covering the latest research on Alzheimer’s, bringing you access to the experts and elevating the patient perspective on what it’s like to live with dementia.
Please help support our mission.
One thought on “A Late-Stage Alzheimer’s Trial Gave Them Hope—Until It Was Canceled”
Thank you Deborah Kan and Being Patient for allowing Kim and I to tell our story about our clinical trial experience.